Improved survival with bevacizumab in advanced cervical cancer Comment uri icon

Overview

MeSH Major

  • Medical Oncology
  • Melanoma
  • Practice Guidelines as Topic
  • Vaginal Neoplasms
  • Vulvar Neoplasms

abstract

  • The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall survival. (Funded by the National Cancer Institute; GOG 240 ClinicalTrials.gov number, NCT00803062.).

publication date

  • January 2014

Research

keywords

  • Comment

Identity

Digital Object Identifier (DOI)

  • 10.1097/01.ogx.0000451484.02983.78

Additional Document Info

start page

  • 734

end page

  • 43

volume

  • 69

number

  • 6